Kopran Limited has informed the Exchange about Observation Letter received from BSE Limited on the Scheme of Amalgamation.
KOPRAN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kopran Limited has received a 'no adverse observations' letter from BSE Limited on February 26, 2026, for its proposed merger by absorption of Kopran Laboratories Limited (Transferor Company) into Kopran Limited (Transferee Company). The Board had first approved the scheme on March 20, 2025. BSE has asked the company to make several disclosures to shareholders, including pre- and post-scheme shareholding pattern, swap ratio rationale, synergy details, financial details of both companies for the last 3 years, and any pending legal actions. Importantly, the observation letter notes that public shareholders' shareholding will decrease while promoter shareholding will increase post-scheme. The BSE observation letter is valid for six months, within which the company must file the scheme with NCLT for further approval.
This is a procedural milestone in the merger process, moving it closer to NCLT approval. However, public shareholders should note the dilution risk as promoter holding will increase after the scheme. The merger could simplify the group structure but final terms (swap ratio) and impact on shareholder value will only be clear once shareholder and NCLT approvals are obtained.